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Abstract
Background: Women infected with HIV have a risk of preterm birth (PTB) that is twice that among uninfected women,
and treatment with antiretroviral therapy (ART) may further increase this risk. Progesterone supplementation reduces the
risk of preterm delivery in women who have a shortened cervix in the midtrimester. We propose to study the feasibility
of a trial of vaginal progesterone (VP) to prevent PTB among HIV-infected women receiving ART in pregnancy. Given low
adherence among women self-administering vaginal study product in recent microbicide trials, we plan to investigate
whether adequate adherence to VP can be achieved prior to launching a full-scale efficacy trial.
Methods and design: One hundred forty HIV-infected pregnant women in Lusaka, Zambia, will be randomly allocated
to daily self-administration of either VP or matched placebo, starting between 20 and 24 gestational weeks. The primary
outcome will be adherence, defined as the proportion of participants who achieve at least 80% use of study product,
assessed objectively with a validated dye stain assay that confirms vaginal insertion of returned single-use applicators.
Secondary outcomes will be study uptake, retention, and preliminary efficacy. We will concurrently perform semi-
structured interviews with participants enrolled in the study and with women who decline enrollment to assess
the acceptability of VP to prevent PTB and of enrollment to a randomized controlled trial.
Discussion: We hypothesize that VP could prevent PTB among women receiving ART in pregnancy. In preparation for
a trial to test this hypothesis, we plan to assess whether participants will be adherent to study product and protocol.
Trial registration: ClinicalTrial.gov, NCT02970552.
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Background
An estimated 15 million babies are born prior to
37 weeks of gestation every year, one million of whom
die as a direct result of their prematurity [1]. Over 60%
of the world’s preterm deliveries occur in Africa and
South Asia; in sub-Saharan Africa, the rate of preterm
birth (PTB) approaches 20%, compared to rates below
10% in the Global North [2]. This disparity can be partly
explained by the elevated risk of PTB faced by HIV-
infected women, some 85% of whom live in sub-Saharan
Africa [3]. Expanded access to HIV antiretroviral therapy
(ART) has transformed the health of mothers and can
prevent most cases of vertical transmission. However, an
unanticipated consequence has arisen: ART use in preg-
nancy appears to increase the risk of PTB even beyond
that attributable to HIV infection itself [4–14].
Declining concentrations of circulating progesterone
and reduced progesterone activity are associated with pre-
term labor [15]. With supplementation, higher serum con-
centrations of progesterone have incremental protection
against preterm labor [16]. Prenatal progesterone—an
anti-inflammatory hormone administered intramuscularly
or vaginally—can reduce the risk of PTB in women who
have had a prior spontaneous PTB and in those with
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evidence of cervical shortening via midtrimester sonog-
raphy [17–20]. HIV infection causes immune activation
and inflammation, both systemically and in the lower
genital tract [21, 22]. While suppressive ART generally im-
proves systemic inflammation, its inconsistent effect on
the lower genital tract may underlie the observed amplifi-
cation of PTB risk [23–25]. Progesterone has been tested
to reduce PTB for numerous high-risk indications, but
has yet to be studied in HIV-infected women.
Our objective is to determine whether VP prophylaxis
may reduce PTB among HIV-infected women receiving
ART in pregnancy. We introduce the study protocol for
a pilot study investigating the feasibility of a rando-
mized controlled trial (RCT) of VP among HIV-
infected gravidas taking ART in Lusaka, Zambia. Given
recently reported challenges to adherence among young
women in vaginal microbicide and HIV pre-exposure
prophylaxis (PrEP) trials in sub-Saharan Africa [26, 27],
it is prudent to investigate whether adequate adherence
can be achieved with VP prior to launching a full-scale
efficacy trial. In this mixed method design, we plan a
pilot study in which 140 participants are randomized to
either VP or placebo and a qualitative component
investigating the acceptability of such a study. The re-
sults of these activities will allow the iterative develop-
ment of study-specific standard operating procedures
meant to optimize uptake, enrollment, adherence, and
retention for a full-scale efficacy trial.
Methods and design
Study design
This is a mixed method study to evaluate the feasibility
and acceptability of a RCT of VP to prevent PTB
among HIV-infected Zambian women. To assess the
feasibility of a full-scale efficacy trial, we will implement
a pilot double-blinded placebo-controlled trial of VP
among HIV-infected pregnant women attending ante-
natal care (ANC) at the University Teaching Hospital
(UTH), the referral hospital in Zambia’s capital city,
Lusaka. To assess acceptability of a RCT to test VP
among this population, we will employ a qualitative
approach of longitudinal semi-structured interviews
(SSI) among women agreeing to trial participation and
a one-time SSI among those who decline to participate.
This study has been designed in accordance with the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT 2013) [28] (Fig. 1, participant
flow diagram).
Study participants
Pregnant women who meet the following criteria will be
eligible for enrollment: (1) 18 years of age or older; (2)
viable intrauterine pregnancy confirmed by ultrasound;
(3) presentation to ANC prior to 24 weeks gestation; (4)
antibody-confirmed HIV-1 infection; (5) initiating or
continuing ART treatment in pregnancy; (6) ability and
willingness to provide written informed consent; and (7)
willing to adhere to study visit schedule. We will exclude
from study participation women with any of the follo-
wing: (1) multiple gestation; (2) non-research indication
for antenatal progesterone supplementation (i.e., prior
spontaneous PTB and/or cervical length ≤20 mm on
screening ultrasound); (3) planned or in situ cervical
cerclage; (4) evidence of threatened abortion, preterm
labor, or ruptured membranes during the current preg-
nancy; (5) major fetal anomaly detected on screening
ultrasound; (6) known uterine anomaly; and (7) known
or suspected allergy or contraindication to VP or pla-
cebo components.
Intervention
Participants will be randomly assigned in a 1:1 ratio to
intervention or placebo in a pilot RCT. The intervention
group will self-administer one 200 mg VP suppository
daily starting prior to 24 weeks gestational age (GA); the
control group will self-administer indistinguishable pla-
cebo daily starting prior to 24 weeks GA. Participants
and study staff will be masked as to treatment allocation.
The qualitative activities of this study will involve two
groups. Women who decline enrollment into the ran-
domized pilot study will be invited to participate in a
one-time face-to-face SSI, while a random sample of the
women choosing to participate in the RCT will be
followed longitudinally with three serial SSIs.
Primary objective
Our primary objective in this trial is to determine whether
a full-scale efficacy trial will be feasible in this setting.
Toward this end, we will study three key indices of feasi-
bility: (1) study uptake, defined as the proportion of
eligible women who agree to be enrolled; (2) adherence to
study product, defined as the proportion of women taking
≥80% of prescribed product doses; [17, 29]; and (3) study
retention, defined as the proportion of women enrolled
for whom we are able to ascertain both the date of
delivery and the infant vital status to define the PTB
outcome. We will assess feasibility of a phase III trial with
the following criteria for marking success:
1. At least 50% of eligible participants agree to be
enrolled.
2. At least 70% of participants achieve adequate
adherence (i.e., ≥70% of women taking ≥80% of
prescribed study product doses).
3. At least 90% of participants complete the study
(i.e., evaluable for PTB outcome).
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We expect the feasibility study to meet all of the above
criteria to satisfy requirements for progression to a
phase III trial.
Study procedures
Potential participants will be identified at an early ANC
visit prior to 24 weeks GA (Fig. 2). A study nurse will
approach patients who may be preliminarily eligible by
GA criteria based on reported last menstrual period. After
an information session and determination of potential eli-
gibility, those choosing to participate will undergo an
informed consent process in their preferred language:
English, Nyanja, or Bemba. Study staff will verify antenatal
and HIV history data through a baseline questionnaire
and review of participants’ medical records. All partici-
pants will undergo a screening ultrasound to confirm
ultrasound eligibility (see exclusion criteria in the “Study
participants” section).
Women will then undergo randomization into one of
two study arms between 20 0/7 and 23 6/7 gestational
weeks. Those participants who are screened during the
window of randomization will be asked to return the
next day for their randomization visit to allow them time
to consider the risks and benefits of study participation
and to discuss the study with their family. The trial will
use a paper-based system of sequentially numbered,
opaque, sealed envelopes to assign women 1:1 to active
progesterone or placebo [30]. A statistician not other-
wise associated with the study will design the scheme
using random permuted blocks. All randomization docu-
mentation will be stored in a secure location. At the
time of randomization, the research nurse will allocate
the randomization envelopes in sequence to assign
randomization identification numbers using stan-
dardized procedures. The statistician will compare the
order of randomization to the original list order to verify
strict order of randomization. Progesterone and placebo
vaginal suppositories will be produced and individually
packaged prior to being shipped to Zambia. Packaging
will be non-descript and identical for the two products.
Each progesterone lot and each placebo lot will have a
unique identifying number produced from a random
number generator that will be indexed in a secured
database as either placebo or product, accessible only to
Pregnant women identified as HIV-infected and  
< 24 gestational weeks from ANC clinic 
Invitation to participate in-person at routine ANC visit 
Potential participant agrees to screening 
Assessment of eligibility based on inclusion/exclusion criteria 
questions administered by study staff 
Exclude if declines 
screening 
Exclude if ineligible 
Exclude if declines 
participation 
Invite to participate in 
one-time SSI 
Obtain informed 
consent 
Administer SSI 
N=30 
Double-blinded randomization 
Allocated to VP 
N=70 
Allocated to placebo 
N=70 
Participant attends routine antenatal care visits at  
24, 32 and 36 weeks gestation  
Participant attends VP study visits every 2 weeks to return used 
applicators and replenish supply of vaginal study product 
Final study visit and participant discontinues study product use at 
36 6/7 weeks, membrane rupture, or delivery (whichever is first) 
30 participants 
randomly 
selected to 
participate in 3 
longitudinal SSI 
at:  
 (1) enrollment; 
(2) mid-study;   
 (3) completion 
Loss to follow-up or 
discontinued 
Complete baseline obstetrical and medical history; screening 
ultrasound; confirmatory HIV testing 
Confirm willingness to participate and complete informed consent 
Fig. 1 Participant flow diagram
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the US-based compounding pharmacy and the unblinded
statistician at interim analysis and end of study. Participants
will be assigned randomization numbers that correspond to
either an active or placebo lot number, to be dispensed by
an on-site pharmacist masked as to treatment allocation.
All other research staff members who have contact with
participants will be masked to both treatment allocation
and assigned product lot numbers. Participants will be
instructed to begin daily self-administration of study pro-
duct from the day of randomization (between 200/7 and
236/7 gestational weeks) until 36
6/7 weeks, membrane
rupture, or delivery, whichever is sooner. Women will be
instructed on correct study product use at the
randomization visit and at additional study visits, as needed.
The on-site pharmacist will dispense suppositories with
single-use applicators at 2-week intervals with an additional
14-day buffer to be replenished as needed at subsequent
study visits. Each participant will receive an instructional
sheet on correct product use and storage as well as a
discreet carrier and plastic bags to facilitate return of used
applicators at follow-up study visits. Participants will also
be asked to complete a dose diary.
After randomization, participants will be asked to re-
turn to clinic every 2 weeks for monitoring of adherence
by self-report, review of dose diaries, counting of unused
product, and collection of used applicators. Trained
technicians, masked to study participant and allocation,
will test all returned applicators for evidence of vaginal
insertion using a validated dye stain assay (DSA) [31] as
detailed below. Standardized adherence counseling will
be provided to all participants and tailored based on
dose diary and self-reported low adherence.
Qualitative activities
Women who decline enrollment into the randomized
trial will be invited to participate in a one-time, face-to-
face SSI to assess the following subject areas: (1) perceived
risk of PTB; (2) health beliefs about and attitudes toward
HIV and PTB, and toward a medication for the prevention
of PTB; (3) acceptability of a daily vaginal medication
Fig. 2 Schedule of study events, visits, and assessments
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compared to weekly intramuscular injections (the alterna-
tive formulation of antenatal progesterone); and (4) atti-
tudes toward participation in a double-masked trial that
uses a placebo control. We aim to sequentially interview
at least 30 women who decline enrollment, with the goal
of thematic saturation of data [32, 33].
Women who are enrolled and randomized to either
progesterone or placebo, and who grant permission to
be contacted separately about a qualitative study com-
ponent, will be randomly selected to participate in
three serial SSIs, held at enrollment, mid-study (28–
32 weeks’ gestational age), and postpartum (prior to
discharge). We aim to conduct interviews with women
enrolled in the study to address the same domains out-
lined above, in addition to barriers and facilitators to:
(1) adherence to study product; (2) returning used ap-
plicators, i.e., protocol adherence; and (3) retention in
the study. If our random sample does not include
women from the full range of adherence levels, we will
apply purposeful sampling to capture women of under-
represented adherence levels for a single interview in
their 3rd trimester. Our expected sample size for this
group will be 30 women, based on expectations re-
garding saturation of qualitative themes [32, 33].
All interview sessions will be facilitated by a trained
staff member with previous experience conducting quali-
tative interviews. Interviews will be held in a private
room in the study clinic and are expected to last 30 min
each. Semi-structured interview guides have been de-
veloped and will be used as an aid by the interviewer.
Sessions will be audio-recorded and transcribed verba-
tim, with explicit approval provided by participants via
informed consent. Where translations are needed, we
will have independent reviewers review and translate
those transcriptions to ensure accuracy.
All participants enrolled in this study will receive
their usual antenatal and HIV care through the govern-
ment healthcare system. ANC consists of an initial visit
at less than 16 weeks gestation and follow-up visits no
less frequently than at 24, 32, and 36 weeks gestation
and delivery. GA will be determined by early ultra-
sound; cervical length measurements and fetal
anatomic survey will be performed as early as possible
before 24 weeks. During routine ANC visits, partici-
pants will receive the recommended care and treat-
ment. At each study visit, study staff will screen
participants for the presence of any adverse or serious
adverse events. Medical care for any obstetrical compli-
cations encountered by trial participants will be pro-
vided at an appropriate Ministry of Health facility.
Laboratory procedures
Trained laboratory technicians will test returned vaginal
applicators using an inert dilute food dye (0.05% FD&C
Blue No.1) that produces a distinctive streaked color
when sprayed on polyethylene plastic applicators after
vaginal insertion. Sensitivity and specificity of DSA for
vaginal insertion is reported as 97 and 79%, respectively
[31]. The DSA has been validated in sub-Saharan Africa,
has been accurate at time points up to 4 months after
insertion, and has shown no evidence of cross-
contamination even when used and unused applicators
were commingled in the same container [34].
Primary outcome
Our primary outcome will be the proportion of women
with adequate adherence to study product, defined as
the return of at least 80% of provided vaginal applicators
with DSA positivity.
Sample size
We will pool participants from both arms for the pri-
mary adherence analysis and will also estimate adhe-
rence within each arm to investigate differences by
treatment group. We used the normal approximation
confidence limit approach to choose the sample size for
this study, with the exact binomial confidence interval
(CI) as a sensitivity approach. Using a 95% CI for the
proportion of participants with adequate adherence and
assuming an observed adherence rate of 80%, n = 140
provides a lower confidence limit above 70%. The target
proportion of women achieving adequate adherence is
70–95%. Tables 1 and 2 presents the precision achieved
for outcomes with an observed proportion of 50–95%.
Statistical analysis plan
In addition to our primary adherence outcome, we will
define uptake strictly as the proportion of women
meeting initial (screening) eligibility criteria who are ran-
domized in the trial; the sample used to estimate the
probability of uptake will be larger than n = 140. If
uptake in the pilot is very low, enrollment of a large trial
might not be feasible. Low uptake might also threaten
external validity and policy value. To quantify study
retention, we will calculate the proportion of women
randomized in the trial for whom we are able to ascer-
tain the date of delivery and infant vital status at birth.
For the present study, we will require a clinic visit to
define retention success (either at delivery or postpartum).
We will also explore whether this outcome can be reliably
Table 1 Anticipated precision with n = 140 (pooled)
Observed proportion (adherence, retention)
0.5 0.6 0.7 0.8 0.9 0.95
Normal approximation
of precision
±0.083 ±0.081 ±0.076 ±0.066 ±0.050 ±0.036
Exact binomial 95% CI 0.41,
0.59
0.51,
0.68
0.62,
0.77
0.72,
0.86
0.84,
0.94
0.90,
0.98
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obtained through a home visit or even a telephone call by
comparing reported data to medical records of those
participants retained. Assuming the observed retention
proportion is 95%, our sample size of 140 women will
provide a 95% CI spanning 90–98% (Tables 1 and 2).
The proportion adherent will be compared between
arms with an estimated risk ratio and corresponding
95% CI. We will also explore maternal demographic
and health characteristics associated with adherence,
uptake, and retention if there are sufficient numbers of
cases. Factors found promising in an unadjusted log-
binomial model will be candidates for a multivariable
model. If cell counts are small, exact logistic regression
will be utilized for sensitivity analysis. Secondary effi-
cacy and safety outcomes will include: (a) delivery prior
to 37 weeks gestation; (b) delivery prior to 34 weeks
gestation; (c) birth weight <2500 g; (d) stillbirth; and (e)
adverse events. In an exploratory analysis of these out-
comes, we will conduct descriptive statistics of partici-
pant demographic and clinical features and of the
proportion of participants experiencing the secondary
outcomes of poor obstetrical and neonatal outcomes.
Although our study is not powered for clinical efficacy,
we will perform unadjusted analyses to determine
whether a numerical difference in risk of these secon-
dary efficacy and safety outcomes exists between
women who were randomized to VP compared to those
randomized to placebo. Exploratory analyses will be
stated as such and presented as pilot effect estimates
with a 95% CI; such analyses will provide useful results
for planning a full-scale trial.
We will also investigate whether the use of a pre-
randomization placebo run-in period [35] would be
valuable in a full-scale efficacy trial. Several perinatal
trials [36, 37] including multiple progesterone studies
[18, 38, 39] have used a placebo run-in period to select
participants who are most likely to be adherent prior to
randomization. For a phase III VP trial, one could im-
agine a 2-week run-in period, where women are pro-
vided placebo/inert study product and only those
returning applicators that met a certain adherence
threshold would be randomized. While we do not in-
tend to explicitly pilot this procedure, we will simulate
it by dividing the adherence dataset into the first 2 weeks
versus the remaining weeks and evaluate whether some
initial threshold adherence (e.g., missing no more than
one dose) is predictive of adequate adherence over the
remaining study period. This exercise will allow us to
evaluate the utility of a run-in in the overall context of
phase III planning, when issues such as recruitment and
representativeness are also being considered. Statistical
approaches for diagnostic testing, such as receiver opera-
ting characteristic (ROC) curve analyses (plot of sensitivity
versus 1-specificity), will be used to inform selection of
the non-adherence cut-point. Sensitivity, specificity, posi-
tive predictive value, and negative predictive value of the
chosen cut-point will be estimated with a corresponding
95% exact binomial CI.
Qualitative analysis plan
Our primary qualitative objective is to identify common
facilitators and barriers to trial uptake, vaginal product
adherence, and retention in a clinical trial. We will first
analyze data from women who decline enrollment inde-
pendently from data among those who enroll. Then,
findings from common baseline domains evaluated in
both assessment groups will be compared to identify
commonalities or discrepancies between decliners and
enrollees. The longitudinal data assessed from interviews
with enrolled participants will be compared across time
and between those randomized to placebo versus pro-
gesterone. After translations and transcription, a team of
coders with qualitative data analysis experience will use
qualitative analysis software to organize the transcribed
data. Transcript data will initially be organized based on
the questions in the semi-structured guides. Coders will
read and “memo” each transcript and compare memos
to create a preliminary codebook. They will apply the
codes to significant utterances, comparing their results
periodically (such as every 4–5 interviews) to assess
consistency between coders in order to refine a final
codebook. They will examine codes and utterances for
clusters of meaning to construct themes and maps
reflecting categories and relationships among codes.
They will then examine the themes identified from each
dataset for contrasts and overlaps between them, which
may lead to reconstructions of the existing themes or
the emergence of new subthemes. A summary report of
the analyzed SSI data will be created which will inform
the development of the following materials for the
planned full-scale efficacy and safety trial: study proto-
col, consent forms, adherence monitoring and coun-
seling guide, and provider training materials.
Ethical considerations
Participation in all study activities will be voluntary.
Each participant will provide written, informed consent
prior to enrollment. The study protocol has been ap-
proved by the University of Zambia Biomedical Research
Ethics Committee and the University of North Carolina
Table 2 Anticipated precision with n = 70 (within arm)
Observed proportion (adherence, retention)
0.5 0.6 0.7 0.8 0.9 0.95
Normal approximation
of precision
±0.117 ±0.115 ±0.107 ±0.094 ±0.070 ±0.051
Exact binomial 95% CI 0.38,
0.62
0.48,
0.72
0.58,
0.80
0.69,
0.89
0.80,
0.96
0.88,
0.99
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at Chapel Hill Institutional Review Board. Research staff
who have contact with participants receive protection of
human research participants training prior to participa-
ting in any study activities and every 2 years thereafter.
Key research staff members complete Good Clinical
Practice or Good Clinical Laboratory Practice training,
as applicable.
It is expected that this study will expose participants
to minimal risks. Self-administration of VP may cause
mild discomfort to participants. Side effects and serious
adverse events with VP administration are very rare. At
each study visit, study staff will evaluate participants for
social harms and adverse events. The severity of study-
related adverse events and social harms will be graded
using the National Institute of Health’s Division of AIDS
Table for Grading the Severity of Adult and Pediatric
Adverse Events. Information on adverse events or social
harms that are related to the study drug and all serious
adverse events will be documented on study data forms
and routinely reported to the Principal Investigator or
designee. If the PI, co-investigators, or their designees
determine that study-related adverse events are occur-
ring at an unexpected rate, they will assess the need for
staff re-training, protocol amendment, or study cessa-
tion. All adverse events will be reported to the regulatory
authorities listed above according to their individual
guidelines. In the case of an emergency that would
require unblinding, the statistician will disclose the allo-
cation arm for the individual participant.
Participation in this study also raises the risks of loss
of confidentiality and discomfort with the personal
nature of questions, particularly when discussing HIV
infection or sexual behaviors. At each step in the study,
personnel will protect participant privacy and confiden-
tiality to minimize these risks. All laboratory specimens,
administrative forms, and study data will be identified by
a random study number; data analysis will be performed
using datasets linked to this number only.
Individual participants in the VP arm of the randomized
trial may benefit from a reduction in PTB risk. All partici-
pants may benefit from enhanced health education and
close clinical monitoring. Knowledge generated from this
study has the potential to inform future clinical trials on
the reduction of PTB risk among HIV-infected women,
which may in turn enable policymakers worldwide to
make informed decisions regarding effective interventions
for the prevention of PTB.
Discussion
The convergence of the HIV and preterm birth epi-
demics in sub-Saharan Africa has unveiled unanticipated
consequences among women taking ART to prevent
mother-to-child HIV transmission. As ART coverage
continues to expand in the region, the burden of
neonatal mortality and lifelong complications attribut-
able to prematurity are likely to worsen. Global funding
and research has succeeded in developing new technolo-
gies that improve outcomes for the preterm infant, yet
many of these interventions are not applicable to
resource-constrained settings, and advances in the area
of prematurity prevention have been limited. Low-cost,
high-impact interventions are desperately needed to pre-
vent preterm birth among those at highest risk for
prematurity and its consequences.
In preparation for a trial to test the effectiveness of
vaginal progesterone for the prevention of preterm birth
among HIV-infected women, this pilot study will allow us
to estimate key parameters of trial feasibility: uptake,
adherence, and retention. It will also provide insight into
rates of adverse events and perhaps preliminary efficacy.
Finally, it will help us develop and test study procedures.
The potential knowledge gained from this research could
influence health policy and potentially prevent thousands
of preterm births per year in Zambia alone. If prenatal
progesterone is found to reduce the risk of preterm de-
livery faced by the 1.5 million HIV-infected women who
become pregnant each year worldwide, elimination of
infant HIV infection might be achieved without paying
the price in prematurity-related death and disability.
Abbreviations
ANC: Antenatal care; ART: Antiretroviral therapy; CI: Confidence interval;
DSA: Dye stain assay; GA: Gestational age; HIV: Human immunodeficiency
virus; PrEP: Pre-exposure HIV prophylaxis; PTB: Preterm birth;
RCT: Randomized controlled trial; SSI: Semi-structured interview;
UTH: University Teaching Hospital; VP: Vaginal progesterone
Acknowledgements
The authors thank the University of North Carolina Center for AIDS Research
Social & Behavioral Science Research Core (P30A150410) for their invaluable
assistance in the design of this study.
Funding
The clinical trial presented in this article is funded through an award from the
United States National Institutes of Health (R21 HD090987-01), which supports
J.S.A.S. Trainee support has been provided through the National Institutes of
Health (T32 HD075731) for J.T.P. K.R.M, and J.S.A.S. also receive support in part
by the UNC Center for AIDS Research (P30A150410). The conclusions and opinions
expressed in this article are those of the authors and do not necessarily reflect those
of the National Institutes of Health.
Availability of data and materials
Not applicable.
Authors’ contributions
JTP, BLF, and JSAS conceived of the study question and study design. KRM
performed the required statistical analyses; KRM, BLF, HBM, and AHC planned
and coordinated randomization and pharmacy procedures. JTP, KRM, NMF,
BLF, CEG, HBM, AHC, BV, and JSAS each contributed to the writing of this
manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the University of North Carolina Institutional Review
Board, reference # 16–2174, and by the University of Zambia Research Ethics
Committee, reference # 004-09-16. Informed consent will be obtained from all
participants prior to study enrollment. Any adverse events associated with the
trial will be reported to the regulatory committees listed above. All data obtained
Price et al. Pilot and Feasibility Studies  (2018) 4:21 Page 7 of 9
during this study will be coded, de-identified, and stored in the secure area of
the University of Zambia Teaching Hospital and University of North Carolina
research offices. Only key investigators will have access to this data.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Global Women’s Health, Department of Obstetrics and
Gynecology, University of North Carolina at Chapel Hill, 3009 Old Clinic
Building, Campus Box 7577, Chapel Hill 27599-7577, NC, USA. 2Department
of Obstetrics and Gynaecology, University Teaching Hospital, Lusaka, Zambia.
3Center for AIDS Research, School of Medicine, University of North Carolina
at Chapel Hill, Chapel Hill, NC, USA. 4Pharmaceutical Society of Zambia,
Lusaka, Zambia. 5Eshelman School of Pharmacy, University of North Carolina
at Chapel Hill, Chapel Hill, NC, USA.
Received: 24 November 2016 Accepted: 5 July 2017
References
1. March of Dimes P, Save the Children, WHO. Born too soon: the global
action report on preterm birth. Geneva: WHO; 2012.
2. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and
worldwide estimates of preterm birth rates in the year 2010 with time
trends since 1990 for selected countries: a systematic analysis and
implications. Lancet. 2012;379(9832):2162–72.
3. Joint United Nations Programme on HIV/AIDS. The Gap Report. 2014; http://
www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf.
Accessed 14 Mar 2016.
4. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in
pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the
Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV
Study. AIDS. 1998;12(18):F241–7.
5. Rudin C, Spaenhauer A, Keiser O, et al. Antiretroviral therapy during pregnancy
and premature birth: analysis of Swiss data. HIV Med. 2011;12(4):228–35.
6. van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth
outcomes in South African women receiving highly active antiretroviral
therapy: a retrospective observational study. J Int AIDS Soc. 2011;14:42.
7. Martin F, Taylor GP. Increased rates of preterm delivery are associated with
the initiation of highly active antiretrovial therapy during pregnancy: a
single-center cohort study. J Infect Dis. 2007;196(4):558–61.
8. Darak S, Darak T, Kulkarni S, et al. Effect of highly active antiretroviral
treatment (HAART) during pregnancy on pregnancy outcomes: experiences
from a PMTCT program in western India. AIDS Patient Care STDS. 2013;27(3):
163–70.
9. European Collaborative S, Swiss M, Child HIVCS. Combination antiretroviral
therapy and duration of pregnancy. AIDS. 2000;14(18):2913–20.
10. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected
women starting protease inhibitor therapy during pregnancy: role of the
ritonavir boost? Clin Infect Dis. 2012;54(9):1348–60.
11. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral
therapy and premature delivery in diagnosed HIV-infected women in the
United Kingdom and Ireland. AIDS. 2007;21(8):1019–26.
12. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women
infected with HIV-1 receiving combination antiretroviral therapy before
versus after conception. Sex Transm Infect. 2009;85(2):82–7.
13. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy
outcomes in HIV-infected women treated with highly active antiretroviral
therapy in Europe. AIDS. 2004;18(17):2337–9.
14. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and
adverse birth outcomes among HIV-infected women in Botswana. J Infect
Dis. 2012;206(11):1695–705.
15. Mazor M, Hershkowitz R, Ghezzi F, et al. Maternal plasma and amniotic fluid
17 beta-estradiol, progesterone and cortisol concentrations in women with
successfully and unsuccessfully treated preterm labor. Arch Gynecol Obstet.
1996;258(2):89–96.
16. Caritis SN, Venkataramanan R, Thom E, et al. Relationship between 17-alpha
hydroxyprogesterone caproate concentration and spontaneous preterm
birth. Am J Obstet Gynecol. 2014;210(2):e121–6.
17. Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the
rate of preterm birth in women with a sonographic short cervix: a
multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound
Obstet Gynecol. 2011;38(1):18–31.
18. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery
by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):
2379–85.
19. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic
administration of progesterone by vaginal suppository to reduce the
incidence of spontaneous preterm birth in women at increased risk: a
randomized placebo-controlled double-blind study. Am J Obstet Gynecol.
2003;188(2):419–24.
20. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Fetal Medicine
Foundation Second Trimester Screening G. Progesterone and the risk of
preterm birth among women with a short cervix. N Engl J Med. 2007;
357(5):462–9.
21. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection:
causes and consequences. J Pathol. 2008;214(2):231–41.
22. Spencer LY, Christiansen S, Wang CH, et al. Systemic immune activation and
HIV shedding in the female genital tract. J Acquir Immune Defic Syndr.
2016;71(2):155–62.
23. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among
women with low levels of viremia while receiving highly active antiretroviral
therapy. J Acquir Immune Defic Syndr. 2007;44(1):38–42.
24. Cu-Uvin S, Delong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding
among women with below detectable plasma viral load. AIDS. 2010;24(16):
2489–97.
25. Ondoa P, Gautam R, Rusine J, et al. Twelve-month antiretroviral therapy
suppresses plasma and genital viral loads but fails to alter genital levels of
cytokines, in a cohort of HIV-nfected Rwandan women. Plos One. 2015;
10(5):e0127201.
26. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure
prophylaxis for HIV infection among African women. N Engl J Med. 2015;
372(6):509–18.
27. Rees H, Delany-Moretlwe SA, Lombard C, Barond D, Panchia R, Myer L,
Schwartz JL, Doncel GF, Gray G. FACTS 001 Phase III Trial of Pericoital
Tenofovir 1% Gel for HIV Prevention in Women. Seattle: CROI; 2015.
28. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and
elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
29. Norman JE, Marlow N, Messow CM, et al. Vaginal progesterone prophylaxis
for preterm birth (the OPPTIMUM study): a multicentre, randomised,
double-blind trial. Lancet. 2016;387(10033):2106–16.
30. Doig GS, Simpson SF. Randomization and allocation concealment: a
practical guide for researchers. J Crit Care. 2005;20(2):187–91.
31. van der Straten A, Cheng H, Mensch B, et al. Evaluation of 3 approaches for
assessing adherence to vaginal gel application in clinical trials. Sex Transm
Dis. 2013;40(12):950–6.
32. O’Reilly M, Parker N. ‘Unsatisfactory Saturation’: a critical exploration of the
notion of saturated sample sizes in qualitative research. Qual Res.
2012;13(2):190–7.
33. Guest G, Bunce A, Johnson L. How many interviews are enough?
An experiment with data saturation and variability. Field Methods.
2006;18(1):59–82.
34. Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of
utilizing the microbicide applicator compliance assay for use in clinical trials.
Contraception. 2007;76(1):53–6.
35. Blackwelder WC, Hastings BK, Lee ML, Deloria MA. Value of a run-in period
in a drug trial during pregnancy. Control Clin Trials. 1990;11(3):187–98.
36. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in
women at high risk. National Institute of Child Health and Human
Development Network of Maternal-Fetal Medicine Units. N Engl J Med.
1998;338(11):701–5.
37. Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-
dose aspirin in healthy, nulliparous pregnant women. The National Institute
Price et al. Pilot and Feasibility Studies  (2018) 4:21 Page 8 of 9
of Child Health and Human Development Network of Maternal-Fetal
Medicine Units. N Engl J Med. 1993;329(17):1213–8.
38. Rouse DJ, Caritis SN, Peaceman AM, et al. A trial of 17 alpha-
hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J
Med. 2007;357(5):454–61.
39. Caritis SN, Rouse DJ, Peaceman AM, et al. Prevention of preterm birth in
triplets using 17 alpha-hydroxyprogesterone caproate: a randomized
controlled trial. Obstet Gynecol. 2009;113(2 Pt 1):285–92.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Price et al. Pilot and Feasibility Studies  (2018) 4:21 Page 9 of 9
